Open AccessEfficacy of antiinflammatory therapy in patients with severe asthma and cold air-provoked bronchial hyperresponsiveness
Author(s) -
А. Б. Пирогов,
Anna Prikhodko,
Дина Гассан,
Т. А. Мальцева,
Victor P. Кolosov,
Ю. М. Перельман
Publication year - 2018
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 6
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2018-28-5-576-583
Subject(s) - medicine , fluticasone propionate , salmeterol , sputum , eosinophil , asthma , bronchial hyperresponsiveness , gastroenterology , fluticasone , montelukast , immunology , respiratory disease , lung , pathology , tuberculosis
The aim of this study was to assess effects of antiinflammatory therapy with leukotriene receptor antagonists (LTA) and/or combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) on the clinical course and airway inflammatory patterns in patients with severe asthma and cold air-provoked bronchial hyperresponsiveness. Methods. Asthma symptoms, lung function, and spontaneous sputum cytology were assessed at baseline and after 24 weeks of the therapy. Subgroup analysis was performed for patients with sputum eosinophils 0.05) after treatment. Conclusion. Adding montelukast to the combined therapy with fluticasone propionate/salmeterol in patients with severe asthma, cold air-provoked bronchial hyperresponsiveness and increased sputum neutrophils did not resulted in better control of the disease. The analysis of airway inflammatory pattern could be used as an additional marker to predict treatment efficiency.